SCHEMBL648666

SCHEMBL648666

O=C1NC(=Nc2ccccc2)SC1=Cc1cnc(Cl)s1

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NPC1 O15118 3/20 0.61
POLB P06746 3/20 0.61
RAB9A P51151 2/20 0.61
SMN1; SMN2 Q16637 2/20 0.61
TDP1 Q9NUW8 1/20 0.61
MEN1 O00255 5/20 0.61
KMT2A Q03164 5/20 0.61
GSK3B P49841 3/20 0.58
MAPT P10636 4/20 0.58
CDC25A P30304 2/20 0.55
CDC25B P30305 2/20 0.55
DYRK1A Q13627 4/20 0.55
CSNK2A1 P68400 3/20 0.55
CSNK2A2 P19784 1/20 0.55
CSNK2B P67870 1/20 0.55
CSNK2A3 Q8NEV1 1/20 0.55
DYRK1B Q9Y463 1/20 0.55
MAP4K4 O95819 3/20 0.52
PIM1 P11309 3/20 0.52
PIM3 Q86V86 3/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL648557 1.00 NPC1 (0.61) NPC1POLBRAB9ASMN1; SMN2TDP1
SCHEMBL649057 0.87 NPC1 (0.62) NPC1POLBRAB9ASMN1; SMN2TDP1
SCHEMBL650962 0.87 NPC1 (0.62) NPC1POLBRAB9ASMN1; SMN2TDP1
SCHEMBL649939 0.86 NPC1 (0.61) NPC1POLBRAB9ASMN1; SMN2TDP1
SCHEMBL649940 0.86 NPC1 (0.61) NPC1POLBRAB9ASMN1; SMN2TDP1
SCHEMBL650335 0.83 NPC1 (0.58) NPC1POLBRAB9ASMN1; SMN2TDP1
SCHEMBL650336 0.83 NPC1 (0.58) NPC1POLBRAB9ASMN1; SMN2TDP1
SCHEMBL649520 0.81 NPC1 (0.67) NPC1POLBRAB9ASMN1; SMN2TDP1
SCHEMBL649519 0.81 NPC1 (0.67) NPC1POLBRAB9ASMN1; SMN2TDP1
SCHEMBL649879 0.80 NPC1 (0.55) NPC1POLBRAB9ASMN1; SMN2TDP1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2423204-A1 THIAZOLIDINONE DERIVATIVE SBI Biotech Co., Ltd. (JP) 2012-02-29 EP disclosed
US-8119812-B2 Thiazolidinone derivative SBI BIOTECH CO., LTD. (JP) 2012-02-21 US disclosed
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE SBI BIOTECH CO., LTD. (JP) 2011-08-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110190299-A1 THIAZOLIDINONE DERIVATIVE CDC7, CDK17, CDCA2 NPC1 1074/4885POLB 2967/4885RAB9A 3157/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.